Cancer research
Researchers from the University of Texas Southwestern Medical Center have discovered that downregulation of the DAB2IP gene in prostate cancer cells results in resistance to ionizing radiation. This finding suggests that DAB2IP plays a crucial role in prostate cell survival following radiation exposure. The study, published in Cancer Research, reveals
Cancer research
Scientists at the University of Pennsylvania have found that combining the cancer drug 5-fluorouracil with a treatment that restores the p53 pathway can effectively deplete putative colon cancer stem cells. This is a significant breakthrough in the field of cancer research, as cancer stem cells are thought to be responsible
Cancer
Research published in the Biochemical and Biophysical Research Communications journal has identified a novel link between p53 family proteins and fibroblast growth factor receptor 3 (FGFR3) expression. Scientists studying the p53 family members, including p53, p63, and p73, found that these proteins regulate FGFR3 expression. This discovery may help understand
Cancer
Researchers at the University of Birmingham have discovered a critical role of CD40 and its ligand (CD40L) in coordinating immune responses, and have found that altering the level of CD40 engagement can induce cell death in carcinoma cells. The team has developed a novel adenovirus that expresses a mutant CD40L
Cancer treatment
A recent phase 1b study published in the journal Clinical Cancer Research has shed new light on the treatment of advanced non-small cell lung cancer (NSCLC). Researchers from the University of Texas M.D. Anderson Cancer Center investigated the safety and efficacy of motesanib, an oral angiogenesis inhibitor, in combination
Cancer treatment
Scientists from Korea have developed a novel approach to cancer gene therapy, utilizing a group I intron of Tetrahymena thermophila to target telomerase reverse transcriptase (TERT) activity in cancer cells. The TERT enzyme is highly upregulated in 85-90% of human cancers, making it a promising target for anticancer therapy. The
Cancer treatment
Recent research from the United States has shed light on the mechanisms underlying histone deacetylase inhibitor (HDACI)-mediated NF-kappaB activation in human leukemia cells. The study, conducted by R.R. Rosato and colleagues from Virginia Commonwealth University, Department of Medicine, investigated the effects of LBH-589, a histone deacetylase inhibitor, on
Cancer treatment
A new approach to breast cancer therapy has been developed using a modified human telomerase reverse transcriptase (hTERT) promoter-directed oncolytic adenovirus that targets the TGFbeta pathway. Researchers from Northwestern University have created a virus, mhTERTAd.sTbetaRFc, that replicates in breast cancer cells while inhibiting TGFbeta signaling. The study demonstrates the
Cancer treatment
Researchers have made significant progress in understanding the role of the histone methyltransferase DOT1L in the development and transformation of leukemia. According to a study published in Expert Opinion On Therapeutic Targets, DOT1L is responsible for methylation of histone H3 at lysine 79 and is involved in the pathobiology of
Cancer treatment
Malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytomas, are the most common primary brain tumors. Despite multimodal treatment including surgery, chemotherapy, and radiation, median survival for patients with GBMs is only 12 to 15 months. Identifying molecules critical for glioma progression is crucial for devising effective targeted therapy. Researchers
Drugs
Researchers from the Capital Medical University, College of Pharmaceutical Sciences in Beijing, People's Republic of China, have made significant findings in the discovery of anti-tumoral indoles. A series of benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indole-2-substituted acetates
Drugs
Oncolytics Biotech Inc. has announced the initiation of a US Phase 2 clinical trial utilizing intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs (SCC lung cancer). This clinical trial aims to assess the antitumor effect of the treatment regimen
